Drug companies Merck and Ridgeback Biotherapeutics report that their antivral pill molnupravir may be a tremendous help protecting patients infected with COVID-19. According to clinical trial data from an interim analysis 29 days after the study began, "molnupiravir reduced the risk of hospitalization or death by approximately 50%" for people with mild to moderate COVID-19. — Read the rest
